Impact of Neoadjuvant Immunochemotherapy on Surgical Outcomes in Management of Early Triple-Negative Breast Cancer
{{output}}
Background: Triple-negative breast cancer (TNBC) is an aggressive subtype with poor prognosis. Neoadjuvant immunochemotherapy (NAIC) combining chemotherapy and pembrolizumab is now standard for Stage II-III TNBC. This study evalu... ...